Coya Therapeutics (NASDAQ:COYA) and Agenus (NASDAQ:AGEN) Head to Head Review

Agenus (NASDAQ:AGEN) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Earnings & Valuation

This table compares Agenus and Coya Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$133.95 million	2.32	$120,000.00	$0.66	10.39
Coya Therapeutics	$4.69 million	16.73	-$21.23 million	($1.39)	-2.41

Agenus has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Agenus and Coya Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	0	2	4	0	2.67
Coya Therapeutics	1	0	5	0	2.67

Agenus currently has a consensus price target of $25.00, suggesting a potential upside of 264.70%. Coya Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 348.43%. Given Coya Therapeutics’ higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than Agenus.

Risk and Volatility

Agenus has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Institutional & Insider Ownership

61.5% of Agenus shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 6.5% of Agenus shares are held by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Agenus and Coya Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agenus	22.10%	-27.16%	26.91%
Coya Therapeutics	-643.44%	-66.91%	-60.13%

Summary

Agenus beats Coya Therapeutics on 10 of the 13 factors compared between the two stocks.

About Agenus

Agenus Inc. is a biotechnology company focused on developing immunotherapies for cancer. Its research and development programs use approaches such as antibody treatments, cancer vaccines, immune-system adjuvants and cell therapies. The company’s clinical-stage pipeline includes botensilimab, an investigational anti-CTLA-4 antibody, and balstilimab, an investigational anti-PD-1 antibody. Agenus is studying these therapies, including in combination, for potential use against several types of cancer.

About Coya Therapeutics

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.